Sensitivity, Specificity, and Predictors of Positive 68Ga–Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis

European Urology

Volumn 70, Issue 6, 2016, Pages 926-937

  Perera, Marlon ^a   Papa, Nathan ^a   Christidis, Daniel ^a   Wetherell, David ^a   Hofman, Michael S ^b   Murphy, Declan G ^a,d   Bolton, Damien ^a,c   Lawrentschuk, Nathan ^a,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c AUSTIN HEALTH   (Australia)

^d EPWORTH HEALTHCARE   (Australia)

Author keywords

Biochemical recurrence; Imaging; Metastases; Positron emission tomography; Prostate cancer; Prostate specific antigen; Prostate specific membrane antigen; Sensitivity

Indexed keywords

GALLIUM 68; PROSTATE SPECIFIC MEMBRANE ANTIGEN; EDETIC ACID; GLU-NH-CO-NH-LYS-(AHX)-((68)GA(HBED-CC)); OLIGOPEPTIDE;

ADVANCED CANCER; BIOCHEMICAL RECURRENCE; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; HUMAN; LYMPH NODE DISSECTION; META ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; ANALOGS AND DERIVATIVES; DIAGNOSTIC IMAGING; MALE; PATHOLOGY; PROSTATE TUMOR;

EDETIC ACID; HUMANS; MALE; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 84979656091     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2016.06.021     Document Type: Review

References (60)

1. [1] Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., Jemal, A., Global cancer statistics, 2012. Cancer J Clin 65 (2015), 87–108.
2. [2] Bartsch, G., Horninger, W., Klocker, H., et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 58 (2001), 417–424.
3. [3] Yu, C.Y., Desai, B., Ji, L., Groshen, S., Jadvar, H., Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature. Am J Nucl Med Mol Imaging 4 (2014), 580–601.
4. [4] Beresford, M.J., Gillatt, D., Benson, R.J., Ajithkumar, T., A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence. Clin Oncol 22 (2010), 46–55.
5. [5] Evangelista, L., Guttilla, A., Zattoni, F., Muzzio, P.C., Zattoni, F., Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol 63 (2013), 1040–1048.
6. [6] DeMarzo, A.M., Nelson, W.G., Isaacs, W.B., Epstein, J.I., Pathological and molecular aspects of prostate cancer. Lancet 361 (2003), 955–964.
7. [7] Huang, E., Teh, B.S., Mody, D.R., Carpenter, L.S., Butler, E.B., Prostate adenocarcinoma presenting with inguinal lymphadenopathy. Urology, 61, 2003, 463.
8. [8] Wu, L.M., Xu, J.R., Ye, Y.Q., Lu, Q., Hu, J.N., The clinical value of diffusion-weighted imaging in combination with T2-weighted imaging in diagnosing prostate carcinoma: a systematic review and meta-analysis. Am J Roentgenol 199 (2012), 103–110.
9. [9] Silver, D.A., Pellicer, I., Fair, W.R., Heston, W.D., Cordon-Cardo, C., Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3 (1997), 81–85.
10. [10] Bostwick, D.G., Pacelli, A., Blute, M., Roche, P., Murphy, G.P., Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 82 (1998), 2256–2261.
11. [11] Evans, M.J., Smith-Jones, P.M., Wongvipat, J., et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A 108 (2011), 9578–9582.
12. 111In-labelled murine antibody in the evaluation of prostate cancer. Biodrugs 13 (2000), 437–447.
13. 89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging 41 (2014), 2093–2105.
14. [14] Afshar-Oromieh, A., Avtzi, E., Giesel, F.L., et al. The diagnostic value of PET/CT imaging with the Ga-68-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42 (2015), 197–209.
15. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconj Chem 23 (2012), 688–697.
16. 18F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol 17 (2015), 565–574.
17. [17] Rowe, S.P., Macura, K.J., Ciarallo, A., et al. Comparison of prostate-specific membrane antigen based F-18-DCFBC PET/CT to conventional imaging modalities for detection of hormone-naive and castration-resistant metastatic prostate cancer. J Nucl Med 57 (2016), 46–53.
18. 99mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates. Bioorg Med Chem Lett 23 (2013), 1557–1563.
19. [19] Afshar-Oromieh, A., Zechmann, C.M., Malcher, A., et al. Comparison of PET imaging with a Ga-68-labelled PSMA ligand and F-18-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 41 (2014), 11–20.
20. [20] Liberati, A., Altman, D.G., Tetzlaff, J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Br Med J, 339, 2009, b2700.
21. [21] Higgins, J.P., Green, S., Cochrane handbook for systematic reviews of interventions. 2008, Wiley-Blackwell, Chichester.
22. [22] Whiting, P.F., Rutjes, A.W., Westwood, M.E., et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155 (2011), 529–536.
23. [23] Nyaga, V.N., Arbyn, M., Aerts, M., Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health, 72, 2014, 39.
24. [24] Barendregt, J.J., Doi, S.A., Lee, Y.Y., Norman, R.E., Vos, T., Meta-analysis of prevalence. J Epidemiol Community Health 67 (2013), 974–978.
25. [25] Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. Br Med J 327 (2003), 557–560.
26. [26] Miller, J., The inverse of the Freeman-Tukey double arcsine transformation. Am Stat, 32, 1978, 138.
27. [27] Dwamena B. Midas: a program for meta-analytical integration of diagnostic accuracy studies in Stata. Ann Arbor, MI: Division of Nuclear Medicine, Department of Radiology, University of Michigan Medical School; 2007.
28. 18F-choline-PET/CT. Clin Nucl Med 41 (2016), 515–521.
29. 68Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol 69 (2016), 393–396.
30. [30] Ceci, F., Uprimny, C., Nilica, B., et al. Ga-68-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?. Eur J Nucl Med Mol Imaging 42 (2015), 1284–1294.
31. [31] Demirkol, M.O., Acar, O., Ucar, B., Ramazanotlu, S.R., Satlican, Y., Esen, T., Prostate-specific membrane antigen-based imaging in prostate cancer: impact on clinical decision making process. Prostate 75 (2015), 748–757.
32. 68Ga]-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol 17 (2015), 575–584.
33. [33] Eiber, M., Maurer, T., Souvatzoglou, M., et al. Evaluation of hybrid Ga-68-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 56 (2015), 668–674.
34. [34] Freitag, M.T., Radtke, J.P., Hadaschik, B.A., et al. Comparison of hybrid Ga-68-PSMA PET/MRI and Ga-68-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. Eur J Nucl Med Mol Imaging 43 (2016), 70–83.
35. [35] Giesel, F.L., Fiedler, H., Stefanova, M., et al. PSMA PET/CT with Glu-urea-Lys-(Ahx)-[Ga-68(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42 (2015), 1794–1800.
36. 68Ga-PSMA positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer. Eur Urol 70 (2016), 553–557.
37. [37] Kabasakal, L., Demirci, E., Ocak, M., et al. Evaluation of PSMA PET/CT imaging using a Ga-68-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl Med Commun 36 (2015), 582–587.
38. 68gallium-PSMA positron emission tomography compared to conventional imaging in lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol 195 (2016), 1436–1443.
39. 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med 56 (2015), 1185–1190.
40. [41] Pfister, D., Porres, D., Heidenreich, A., et al. Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with 68Ga-PSMA-HBED-CC than with 18F-fluoroethylcholine PET/CT. Eur J Nucl Med Mol Imaging 43 (2016), 1410–1417.
41. 68Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer. Eur J Nucl Med Mol Imaging 43 (2016), 1288–1299.
42. 68Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma. Eur J Nucl Med Mol Imaging 43 (2016), 898–905.
43. [44] Sterzing, F., Kratochwil, C., Fiedler, H., et al. Ga-68-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. Eur J Nucl Med Mol Imaging 43 (2016), 34–41.
44. 68Ga-Prostate-specific membrane antigen has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU Int 117 (2016), 732–739.
45. 68Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. Eur J Nucl Med Mol Imaging 43 (2016), 397–403.
46. [47] D'Amico, A.V., Whittington, R., Malkowicz, S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998), 969–974.
47. [48] Hovels, A.M., Heesakkers, R.A., Adang, E.M., et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 63 (2008), 387–395.
48. 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients. Eur J Nucl Med Mol Imaging. 40:Suppl 1 (2013), S18–S27.
49. 18F-fluorodeoxyglucose PET/CT: utility and limitations. Eur J Nucl Med Mol Imaging 40:Suppl 1 (2013), S5–S10.
50. [51] Mohsen, B., Giorgio, T., Rasoul, Z.S., et al. Application of C-11-acetate positron-emission tomography (PET) imaging in prostate cancer: systematic review and meta-analysis of the literature. BJU Int 112 (2013), 1062–1072.
51. 18F]-fluorocholine PET-CT and pelvic MRI with diffusion-weighted imaging for staging in patients with high-risk prostate cancer. Prostate 75 (2015), 323–331.
52. 11C]Acetate positron emission tomography-computed tomography imaging of prostate cancer lymph-node metastases correlated with histopathological findings after extended lymphadenectomy. Scand J Urol 49 (2015), 35–42.
53. [54] European Association of Urology. Guidelines on prostate cancer; 2015. http://uroweb.org/guideline/prostate-cancer/.
54. [55] Afshar-Oromieh, A., Haberkorn, U., Hadaschik, B., et al. PET/MRI with a Ga-68-PSMA ligand for the detection of prostate cancer. Eur J Nucl Med Mol Imaging 40 (2013), 1629–1630.
55. 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. J Nucl Med 54 (2013), 833–840.
56. 11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 35 (2008), 18–23.
57. [58] Heidenreich, A., Bastian, P.J., Bellmunt, J., et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65 (2014), 467–479.
58. 68Ga]-labelled PSMA ligand based on PSA value in patients with biochemical recurrent prostate cancer after radical prostatectomy. Eur Urol Suppl, 15, 2016, e565.
59. 68Ga-PSMA PET/CT for biochemical recurrence after radical prostatectomy. Eur Urol Suppl, 15, 2016, e561.
60. [61] Eiber, M., Weirich, G., Holzapfel, K., et al. Simultaneous Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. Eur Urol 70 (2016), 829–836.